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Abstract
Background: Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are important causes
of morbidity and mortality of hemodialysis (HD) patients. This study aimed to investigate the
epidemiological and clinical features of HCV and HBV infections in six different HD units in Kosova.
Five hundred and eighty-three end-stage kidney disease (ESKD) patients on maintenance HD from
six HD centers in Kosova (358 female, 225 male, mean age 54,8 years (16–66) were included in this
study. Data from databank of the National Blood Bank in Prishtina, as well as the data from the
databank of the Transfusion Centers in Regional hospitals in Prizren, Peja, Gjilan, Mitrovica and
Gjakova were taken in this study. Clinical data such as age, sex, HBsAg and anti-HCV antibody and
primary causes of ESKD were examined.
Serological markers for HBV and HCV were determined with immunoenzymatic assay (ELISA).
Results: The T-test and x2 test were used to analyze the significance of the results. Among our
HD patients HBsAg and anti-HCV antibody prevalence rate was 12%, respectively 43%. Chronic
nephritis was a more frequent cause of ESKD among our HD patients. With unknown etiology
were 23, 5% from them.
Conclusion: HBV and HCV prevalence in our HD patients is still high. These data emphasize the
need for stricter adherence to infection control, barrier precaution and preventive behaviors with
all patients.
Background
Hemodialysis (HD) patients are at high risk for viral hep-
atitis infections due to the high number of blood transfu-
sion sessions, prolonged vascular access and the potential
for exposure to infected patients and contaminated equip-
ment [1,2].
The prevalence of HCV antibodies in nephrology units is
high and has been reported to range from 5 to 54% [3].
HBV infection is less prevalent than HCV in HD units [4].
The rate of serum HBsAg seropositivity on maintenance
HD in the developed world is currently low (0–10%) but
outbreaks of acute HBV infection continue to occur in this
setting. The prevalence of HBV infection within dialysis
units in developing countries appears higher (2–20%)
based on relatively several reports [5].
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The aim of the present study was to investigate the epide-
miological and clinical features of HCV and HBV infec-
tions in six different HD units in Kosova.
Methods
Clinical and epidemiological data were obtained from
January to December 2008 in six different HD units in
Kosova (Prishtina with 150, Prizren with 110, Peja with
74, Gjilani 80, Mitrovica 71 and Gjakova with 31
patients). Data from databank of the National Blood Bank
in Prishtina as well the data from the above mentioned
transfusion centers were used in this study. Clinical data
such as age, sex, HBsAg and anti-HCV antibody and pri-
mary cause of ESKD were examined.
Serological testing for HBV surface antigen and antibodies
to HCV was performed using microparticle enzyme
immunoassay (Abbott AxSM System, Abbott Laborato-
ries, Abbott Park, Illinois, USA) and appropriate assays
manufactured for the system (Abbott-AxSYM HBsAg ver-
sion 2 and HCV version 3.0 assays). The T-test and x2 test
were used to analyze the significance of the results.
Results
From 583 patients, 358 (61,4%) of them were female and
225(38,6%) were male, and the age ranged from 16–66
years with mean age 54.8 years, (Table 1).
The major primary renal diseases in the end stage of kid-
ney disease (ESKD) patients included chronic nephritis
(23, 2%), diabetes mellitus (19,2%), hypertension
(13,2%), urologic diseases (7,3%), cystic renal diseases
(6,1%), and nonspecific chronic pyelonephritis (6%).
Four patients (0, 7%)were with systemic lupus erytemath-
osus (SLE). There were 23, 5% (137 patients) with
unknown etiology, (Figure 1).
More than 80% of patients were between age 26 and 65
years old whereas only 7.5% of them were younger than
25 year, (Figure 2).
In this study, 70 patients (12%) were HBsAg positive, and
250 of them (43%) were anti HCV positive, (Figure 3).
Disccusion
In patients on maintenance HD, the risk of hepatitis is still
a serious problem despite the availability of serological
tests and vaccines for hepatitis B virus infection and uni-
versal precaution standards and infection control meas-
ures. Available data suggest that HCV has become the
most common cause of acute hepatitis in dialysis patients
and dialysis staff members, following the implementation
of infection control measures for HBV, [6].
In our study, the prevalence of HBsAg was 12%.
Results of the examination which were done with 165 HD
patients from three units in Kosova (Prishtina, Prizren
and Mitrovica) during first six months of 2003 showed
that prevalence of anti HCV antibodies and HBsAg were
38.78%, respectively 24,24%. This study showed that
duration of dialysis and number of transfusions are risk
factors for development of HBV and HCV infection (p < 0,
05) [7].
Table 1: The number and sex of tested patients in Hemodialysis 
Unit
Sex N %
M2 2 5 3 8 . 6
F3 5 8 6 1 . 4
Total 583 100
Etiology of prevalent regular HD patients Figure 1
Etiology of prevalent regular HD patients.
Age distribution of prevalent regular HD patients Figure 2
Age distribution of prevalent regular HD patients.Virology Journal 2009, 6:72 http://www.virologyj.com/content/6/1/72
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The results of our last study demonstrate a decrease in
prevalence of HBV positive HD patients during from 24,
24% to 12% over six years. This decrease of HBV infection
in dialysis patients over the years despite implementation
of universal precaution is a result of advent of recom-
binant human erythropoietin and HBV vaccination in last
years. This prevalence is higher than in USA, Croatia,
Japan, Casablanca, Iran, Jordan, Kenya, Saudi Arabia,
Hong Kong and lower than India, Taiwan, Romania,
Greece, Spain, Turkey and Brazil [8-23].
The HBV prevalence among the blood donors of Kosova
is 4, 2%, which range Kosova to the second zone accord-
ing to the CDC classification of the geographical expand-
ing of the HBV infection. The HCV prevalence among the
blood donors in Kosova is 0,3%, compared to other Euro-
pean countries this level of prevalence is relatively low
[24].
Results of the study which were done with Kosovar refu-
gees who had arrived in southern Italy in 1999 revealed
that HBV infection seems to be at an intermediate level of
endemicity. At the same time this study indicates that the
level of endemicity of HCV infection in Kosovar popula-
tion is low [25].
HCV prevalence in HD varies geographically, both within
and between countries [26].
The reported anti-HCV seropositivity since 1999 ranges
from low (1.9%) in the Slovenia [27] to high (80%) in
Senegal [28]. HCV seroprevalence in the HD population
was 59% in Bosnia and Herzegovina, 6.8% in Belgium,
16.3% in France, 6.1% in Germany, 10%–29% in Greece,
22.5%–32.1% in Italy, 75% in Moldavia, 3.4% in the
Netherlands, 11% in Sweden, 7%–23.3% in the USA, 4%
in the UK, 20.5% in Libya, 71% in Kuwait, 23.7% in
Sudan, 19% – 41.7% in Tunisia, 8.4%–43.2% in Brazil,
6.7% in Mexico, 59.3% in Peru, 3.5% in Puerto Rico and
13.2% in Iran [29-47]
The prevalence of HCV among our HD patients is 43%,
compared with above mentioned study [7] there is not a
decrease in prevalence of HCV in our HD patients over
last six years. In our opinion environment condition in
our hemodialysis units are responsible for high preva-
lence of HCV in our HD patients.
Conclusion
In summary, the prevalence of HBV and HCV in our HD
patients is still high. These data emphasize the need for
stricter adherence to infection control, barrier precaution
and preventive behaviors with all patients.
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